Corxel's once daily pill from the same gut hormone drug class as Wegovy and Ozempic — coded CX11 — approached injectable weight loss in a 36 week US trial and now heads to its first large scale Phase 3 study.
A once-daily pill from the same drug class as Wegovy and Ozempic just posted a 36-week weight-loss result comparable to the leading injectables, with vomiting in roughly half as many patients and a 5% rate of patients quitting over stomach side effects. The question now is whether that tolerability edge, if it holds in a larger US study, is the adherence unlock the GLP-1 obesity field has been waiting for.
GLP-1 receptor agonists are the medicines behind Novo Nordisk's Wegovy and Ozempic and Eli Lilly's Zepbound. They mimic a gut hormone that suppresses appetite and slows digestion. They produce the largest sustained weight loss of any drug class on the market, but the same gut-hormone effect that curbs appetite also makes many patients nauseated, and a meaningful share vomit in the first weeks of treatment. In real-world practice, that is the most common reason patients stop the drug before reaching the weight loss the label promises.
The new entrant is CX11, an oral small-molecule GLP-1 (a once-daily pill rather than a weekly injection) from Corxel Pharmaceuticals, a clinical-stage cardiometabolic biopharma based in Berkeley Heights, New Jersey. Corxel reported positive top-line results from a US Phase 2 trial of CX11 in adults with obesity or overweight with at least one weight-related comorbidity.
The trial randomized 246 adults across five arms for 36 weeks: three CX11 dosing regimens (120 mg, 160 mg, and 200 mg slow-titration), a 200 mg fast-titration arm, and placebo. At the end of treatment, the highest-dose arms produced mean body-weight reductions of up to 11.5%, with no plateau by week 36. Patients were still losing weight when the study ended.
The tolerability numbers are the story. Across the four active doses, nausea was reported in 33 to 34% of patients, vomiting in 12 to 16%, diarrhea in 4 to 12%, and constipation in 2 to 12%. No severe cases of those gastrointestinal events were reported, and most occurred during dose escalation and subsided once patients reached a maintenance dose. About 5% of patients on CX11 discontinued treatment because of gastrointestinal side effects.
The published Wegovy label reports vomiting in around 25% of patients in its pivotal trials. That is a cross-trial reference, not a head-to-head study, because the trials ran in different populations with different titration schedules. But it is the comparison Corxel is making to position CX11 in an oral market where tolerability has become the limiting factor for adherence.
Bo Liang, chief medical officer of Corxel, said in the company release that the US Phase 2 results are consistent with the VCT220 China Phase 3 data and support advancing to a pivotal global Phase 3 trial. The China data are the credibility anchor. In 840 obese or overweight Chinese adults, Corxel's partner Vincentage Pharma reported a 52-week mean weight reduction of 12.2% on the 120 mg dose and 12.4% on the 160 mg dose. Vincentage is pursuing a China new drug application under the brand name VCT220; CX11 and VCT220 are the same molecule, with Corxel holding global rights outside mainland China under a December 2024 in-licensing deal, according to industry coverage.
The US competitive landscape is more crowded. Eli Lilly's orforglipron, marketed as Foundayo, was FDA-approved in April 2026 as the first oral GLP-1 without food or water restrictions, setting the bar that any new entrant now has to clear on price, access, and tolerability. Pfizer's oral GLP-1 danuglipron has faced a slower path after earlier setbacks. Corxel's pitch is narrower: a small-molecule, once-daily oral GLP-1 with what the company says is a better GI profile than the injectable incumbents and a comparable weight-loss ceiling.
CX11 still has to clear a US Phase 3 before any FDA submission, and that trial has not yet been announced in detail. The data reported so far are company top-line, not peer-reviewed, and there is no published head-to-head study against Wegovy or Zepbound. Manufacturing scale, cold-chain requirements, and pricing all remain open questions for the oral GLP-1 class as a whole. But the GI tolerability comparison is the specific question Phase 3 will have to answer, because if a low-vomiting oral option holds up at scale, it changes the practical calculus for the patients who have so far been unable to stay on injectable therapy long enough to benefit.
Beyond CX11, Corxel's pipeline includes JX10, a thrombolytic and anti-inflammatory in development for acute ischemic stroke, and CX12, an oral small-molecule amylin receptor agonist that targets a different gut-brain hormone pathway and remains in preclinical work.